SOMETHING IS BETTER THAN NOTHING- THE VALUE OF ACTIVE INTERVENTION ON STATED PREFERENCES FOR TREATMENTS TO DELAY ONSET OF ALZHEIMER’S DISEASE SYMPTOMS
Author(s)
Johnson FR1, Disantostefano R2, Reed SD3, Yang J4, Levitan B5
1School of Medicine, Duke University, Durham, NC, USA, 2Janssen R&D, Titusville, NJ, USA, 3Duke School of Medicine, Durham, NC, USA, 4Duke Clinical Research Institute, Durham, NC, USA, 5Janssen Research & Development, Titusville, NJ, USA
OBJECTIVES : To quantify the value of active treatment relative to no treatment for Alzheimer’s Disease (AD) apart from specified treatment benefits, tolerability, and adverse-event risks. METHODS : RESULTS : A choice model for the full sample with an alternative-specific constant for treatment vs. no treatment was statistically significant (beta=1.16, P=0.036) and a maximum acceptable risk (MAR) of mortality for one more year of normal memory of 13% (CI 9%-17%). A surprising 30% of respondents chose the treatment alternative in the dominated-pair validity test. Excluding these respondents and/or respondents who always chose the treatment alternative eliminated the significant label effect and reduced the MAR by about half. Thus, the value of AD treatment, regardless of efficacy or side effects, is equivalent on average to reducing acceptable treatment risk by about 6%. CONCLUSIONS : Patients faced with a terminal condition often are hopeful that treatments that offer little benefit to the average patient will work better in their case. We found significant evidence of this “value of hope” in this study of treatments to delay onset of AD symptoms.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PND39
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Neurological Disorders